Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Return on assets
Moderna, Inc.'s return on assets over the twelve months to 30 June 2026 was −27.4%, down 6.1 percentage points from fiscal 2025 (−21.3%). Over the past ten years it has ranged from −28.9% (fiscal 2019) to 76.3% (fiscal 2021); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −48.0% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −21.3% | 0.56 |
| FY2024 | −21.9% | (0.58) |
| FY2023 | −21.3% | (54.39) |
| FY2022 | 33.1% | (43.15) |
| FY2021 | 76.3% | 92.99 |
| FY2020 | −16.7% | 12.20 |
| FY2019 | −28.9% | (2.56) |
| FY2018 | −26.4% | (4.81) |
| FY2017 | −21.6% | (3.15) |
| FY2016 | −18.4% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ARGX argenex SE compare | 23.2% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 17.1% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 15.3% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 10.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 8.47% |
| RPRX Royalty Pharma PLC compare | 4.26% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| MRNA Moderna, Inc. | −27.4% |
| RVMD Revolution Medicines, Inc. compare | −52.4% |
| Biotechnology industry median | −48.0% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement